Kiniksa touts 3rd approval for aging Arcalyst — a good haul for just $5M in cash it paid Regeneron for the drug
Kiniksa bet $5 million cash back in 2017 that Regeneron’s Arcalyst could help patients with recurrent pericarditis, a painful autoinflammatory heart disease. Now, more than three years later, that bet continues to pay off.
Regulators approved Arcalyst (rilonacept) to treat recurrent pericarditis and reduce the risk of recurrence in patients 12 years and older, Kiniksa said on Thursday. The Bermuda-based biotech is planning a commercial launch — its very first — this April, and will split the profits 50/50 with Regeneron.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
